Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases
about
Chemotherapy- and irradiation-induced bone loss in adults with solid tumorsRecent advances in bone-targeted therapies of metastatic prostate cancerThe best of both worlds - managing the cancer, saving the bone.Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.
P2860
Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Samarium-153-ethylene diamine ...... h osteoblastic bone metastases
@en
Samarium-153-ethylene diamine ...... osteoblastic bone metastases.
@nl
type
label
Samarium-153-ethylene diamine ...... h osteoblastic bone metastases
@en
Samarium-153-ethylene diamine ...... osteoblastic bone metastases.
@nl
prefLabel
Samarium-153-ethylene diamine ...... h osteoblastic bone metastases
@en
Samarium-153-ethylene diamine ...... osteoblastic bone metastases.
@nl
P2093
P2860
P356
P1476
Samarium-153-ethylene diamine ...... h osteoblastic bone metastases
@en
P2093
Candice Johnstone
John Longo
Stephen Lutz
P2860
P304
P356
10.2147/CMAR.S35789
P407
P577
2013-08-13T00:00:00Z